Clinical Trials DEA Patients Programs 
NORML
SEPTEMBER 20, 2019
We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. Essentially, the federal government has monopolized cannabis research, and ElSohly’s product, according to some scientists who’ve seen it, is unsuitable for clinical trials.
Veriheal
JUNE 29, 2021
This Act permits individuals that have been diagnosed with life-threatening conditions or diseases that have exhausted all other approved treatment and therapeutic options that are also unable to participate in clinical trials the ability to access certain treatments that would otherwise be unapproved for access. A Push by Patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
MAY 7, 2020
What you may not know is that the federal government actually has its own stash of cannabis for limited patient distribution and limited research purposes that it houses at the University of Mississippi (a/k/a) Ole Miss in Oxford, Mississippi. for various studies, including FDA-approved clinical trials.
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). The RTT Act.
Veriheal
APRIL 11, 2022
He also emphasized the fact that medical cannabis programs are now legal in 37 states, as well as four out of five inhabited U.S. You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. Drug Enforcement Agency (DEA). territories. This means that U.S. federal law.
SpeedWeed
AUGUST 11, 2021
The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes. We overcame significant regulatory obstacles obstructing cannabis research to conduct the first clinical trial of inhaled cannabis for PTSD ,” said Yazar-Klosinki. . MAPS Makes History.
Cannabis Law Report
APRIL 21, 2022
The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .
Expert insights. Personalized for you.
227 
Let's personalize your content